Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 8/20 | 0.37 |
| ▸ | KDM5A | P29375 | 6/20 | 0.37 |
| ▸ | KDM4A | O75164 | 2/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KDM5C | P41229 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23052949 | 0.98 | KDM4C (0.39) | KDM4CKDM5AKDM4APHF8S1PR2 | |
| SCHEMBL12542134 | 0.91 | MAPT (0.35) | — | |
| SCHEMBL25566723 | 0.86 | CHRM2 (0.37) | — | |
| SCHEMBL25566781 | 0.86 | CHRM2 (0.32) | — | |
| SCHEMBL25828466 | 0.85 | KDM4C (0.39) | KDM4CKDM5AKDM4APHF8S1PR2 | |
| SCHEMBL14584611 | 0.84 | KDM5A (0.34) | KDM4CKDM5APHF8 | |
| SCHEMBL25569661 | 0.84 | CHRM2 (0.39) | — | |
| SCHEMBL23945777 | 0.83 | SIGMAR1 (0.41) | KDM4CKDM5AKDM4APHF8S1PR2 | |
| SCHEMBL16062742 | 0.83 | CYP2C19 (0.41) | CYP1A2 | |
| SCHEMBL10616486 | 0.83 | MAPT (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001845-B2 | Nucleic acid molecules targeting superoxide dismutase 1 (SOD1) | PHIO PHARMACEUTICALS CORP. (US) | 2021-05-11 | — | — | US | disclosed |
| US-20180195072-A1 | NUCLEIC ACID MOLECULES TARGETING SUPEROXIDE DISMUTASE 1 (SOD1) | RXI PHARMACEUTICALS CORPORATION (US) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001845-B2 | Nucleic acid molecules targeting superoxide dismutase 1 (SOD1) | SOD1, SOD3, POLRMT | KDM4C 4338/4885KDM5A 4355/4885KDM4A 4122/4885 |
| US-20180195072-A1 | NUCLEIC ACID MOLECULES TARGETING SUPEROXIDE DISMUTASE 1 (SOD1) | SOD1, SOD3, POLRMT | KDM4C 4338/4885KDM5A 4355/4885KDM4A 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.